title: [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
abstract: Hepatitis B virus (HBV) reactivation after chemotherapy regimens is a well-known complication. The incidence and risk factors for HBV reactivation remain to be elucidated. We aimed to determine the incidence and risk factors for HBV reactivation in patients receiving rituximab, and the potential role of the cumulative rituximab dose in HBV reactivation. We retrospectively reviewed 320 patients receiving rituximab in our hospital. Of these, 42 (13.12%) had serological markers of hepatitis B. During follow-up, 21% (9/42) had HBV reactivation. Risk factors for reactivation were HBsAg positivity (p < 0.05), isolated anti-HBc positivity (p < 0.05), marginal zone lymphoma, and Mantle cell lymphoma (p < 0.05). The median rituximab dose tended to be higher in patients with reactivation (p = 0.06).
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. Electronic address: mlgutierrez@fhalcorcon.es.
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Gutiérrez García
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors.forename: Sonia
authors.initials: S
authors.lastname: Alonso Lopez
authors.affiliation: Servicio de Medicina Preventiva, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Martín Rios
authors.affiliation: Servicio de Farmacia, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors.forename: Patricia
authors.initials: P
authors.lastname: Sanmartin Fenollera
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors.forename: Sandra
authors.initials: S
authors.lastname: Agudo Fernandez
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors.forename: Conrado Manuel
authors.initials: CM
authors.lastname: Fernández Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects*; D014611:Vaccination; D014775:Virus Activation
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: Hematological disease; Hepatitis B virus reactivation; Neoplasias hematológicas; Reactivación del virus de la hepatitis B; Rituximab